Kura Oncology to Participate in SVB Securities Global Biopharma Conference
February 07, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
January 24, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
December 10, 2022 10:30 ET
|
Kura Oncology, Inc.
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated...
Kura Oncology to Host Investor Event on December 10, 2022
December 01, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
November 22, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
November 03, 2022 09:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Third Quarter 2022 Financial Results
November 03, 2022 07:30 ET
|
Kura Oncology, Inc.
– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN...
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
November 03, 2022 07:00 ET
|
Kura Oncology, Inc.
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into...
Kura Oncology to Participate in Two Upcoming Investor Conferences
November 02, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Third Quarter 2022 Financial Results
October 27, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...